# Flagship Pioneering

> Flagship Pioneering is a VC fund backing Biotechnology and Health Care. See 231 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 231
- Last investment: Apr 2026
- Lead investor: 44%
- Last fund: Jul 2024
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/flagship-pioneering
- X (Twitter): https://twitter.com/FlagshipPioneer
- Website: http://flagshippioneering.com

Flagship Pioneering is a VC fund in Cambridge focused on Biotechnology and Health Care. Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.

## Contacts

5 contacts available for Flagship Pioneering. Shizune tracks 24 team members at Flagship Pioneering. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/flagship-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.5M–$75M |
| Series B | $11M–$230M |
| Series C | $12M–$123M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 64 | 28% |
| Health Care | 34 | 15% |
| Medical | 28 | 12% |
| Therapeutics | 21 | 9% |
| Life Science | 13 | 6% |

78 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 47 | 20% |
| Series C | 38 | 16% |
| Series A | 36 | 16% |
| Funding Round | 15 | 6% |
| Series D | 14 | 6% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 92 | 40% |
| Canada | 1 | 0% |
| United Kingdom | 1 | 0% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Geoffrey von Maltzahn | General Partner | 1 | https://shizune.co/investors/profile/geoffrey-von-maltzahn |
| Hari Pujar | Operating Partner | 1 | https://shizune.co/investors/profile/hari-pujar |
| Thomas de Vlaam | Co-Founder FL86 | 3 | https://shizune.co/investors/profile/thomas-de-vlaam |
| Avak Kahvejian | General Partner | 7 | https://shizune.co/investors/profile/avak-kahvejian |
| Bill Johnson | Vice President of Finance | 0 | https://shizune.co/investors/profile/bill-johnson |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Serif Bio­med­i­cines | Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M | Venture - Series Unknown | Apr 21, 2026 |  |
| Serif Bio­med­i­cines | Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M | Venture - Series Unknown | Apr 21, 2026 |  |
| Serif Bio­med­i­cines | Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M | Venture - Series Unknown | Apr 21, 2026 |  |
| Foghorn Therapeutics | Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases. | $50M | Post-IPO Equity | Jan 09, 2026 |  |
| Expedition Medicines | Expedition Medicine's industry-leading chemoproteomics data generating engine learns the rules of molecular reactivity, enabling programmable small molecule medication design. | $50M | Series A | Oct 22, 2025 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $115M | Series A | Oct 14, 2025 |  |
| Extuitive | Extuitive AI agents develop multiple product and ad versions and select the most effective concepts based on market trends. | $20M | Seed | Sep 18, 2025 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $235M | Series A | Sep 14, 2025 |  |
| Terrana Biosciences | Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. |  |  | Jul 01, 2025 |  |
| Terrana Biosciences | Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | $50M | Series B | Jul 01, 2025 |  |

10 of 231 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 25 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 18 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 16 deals together
- [Alaska Permanent Fund](https://shizune.co/investors/profile/alaska-permanent-fund) — VC Fund, 14 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 14 deals together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 13 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Flagship Pioneering invest in?

Flagship Pioneering invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 231 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Flagship Pioneering's check size?

Flagship Pioneering typically joins rounds of $6.5M–$75M at Series A, $11M–$230M at Series B and $12M–$123M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Flagship Pioneering participates in.

### How do I contact Flagship Pioneering?

Public channels for Flagship Pioneering include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Flagship Pioneering?

The team at Flagship Pioneering includes Geoffrey von Maltzahn (General Partner), Hari Pujar (Operating Partner) and Thomas de Vlaam (Co-Founder FL86), among 24 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co